Ser-Ap-Es is an antihypertensive-diuretic combination, available as tablets for oral administration. Each tablet contains Serpasil (reserpine USP), 0.1 mg; Apresoline (hydralazine hydrochloride USP), 25 mg; and Esidrix (hydrochlorothiazide USP), 15 mg.
Ser-Ap-Es (hydralazine/hydrochlorothiazide/reserpine) is indicated for the following:
Hypertension (see boxed WARNING).
Media Articles Related to Ser-Ap-Es (Hydralazine / Hydrochlorothiazide / Reserpine)
Uncovering Endocrine Causes of Hypertension
Source: Medscape Internal Medicine Headlines [2017.04.21]
Dr Arefa Cassoobhoy highlights one of the week's most important news stories for primary care.
Medscape Internal Medicine
Endocrine Society issues statement to improve detection of curable forms of hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2017.04.10]
A new Scientific Statement issued by the Endocrine Society advises healthcare providers on ways to spot hormonal causes of high blood pressure that can be cured with surgery or treated effectively...
High Blood Pressure (Hypertension)
Source: MedicineNet Polycystic Ovary Specialty [2017.03.31]
Title: High Blood Pressure (Hypertension)
Category: Symptoms and Signs
Created: 1/15/2014 12:00:00 AM
Last Editorial Review: 3/31/2017 12:00:00 AM
New role for immune cells in preventing diabetes and hypertension
Source: Hypertension News From Medical News Today [2017.03.20]
Immune cells which are reduced in number by obesity could be a new target to treat diseases such as type 2 diabetes and hypertension that affect overweight people, according to a collaborative...
Study reveals link between hypertension and brain changes in rats
Source: Hypertension News From Medical News Today [2017.03.10]
New research investigates the changes in brain activity and arterial blood flow that occur with the onset of hypertension in rats.